Sun Pharma Advanced Research Company Limited (SPARC) responded to an official query regarding an unusual increase in trading volume for its scrip (BSE Code: 532872) dated March 27, 2026. The company confirmed full compliance with all disclosure requirements under Regulation 30 of the SEBI LODR Regulations, 2015. SPARC stated that it is not aware of any material, undisclosed information that would necessitate a regulatory filing at this time, reaffirming its commitment to timely disclosures.
Response to Exchange Query on Trading Activity
Sun Pharma Advanced Research Company Limited (SPARC) issued a formal response dated March 27, 2026, addressing a recent communication from the stock exchange concerning an unusual increase in the trading volume of its equity shares. The specific query reference number cited was L/SURV/ONL/PV/SG/2025-2026/1006, relating to Scrip Symbol 532872.
Compliance Confirmation
In its formal reply, the Company Secretary and Compliance Officer, Kajal Damania, affirmed that SPARC is operating in strict compliance with the requirements stipulated under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement explicitly states that all disclosures required by this regulation have already been made to the exchanges.
Disclosure Stance
Crucially, the management confirmed that they are currently not aware of any information that qualifies as material information requiring immediate disclosure under the applicable regulations but has not yet been made public. SPARC reiterated its ongoing commitment to maintaining adequate and timely disclosures to the Stock Exchanges as mandated by all applicable laws.
Source: BSE
